千红制药：公司原创一类新药QHRD106已完成二期临床研究并已将相关资料递交CDE

Core Viewpoint - QHRD106, an original first-class new drug developed by the company, has successfully completed phase II clinical trials and is preparing to enter phase III clinical trials pending approval from the CDE [1] Group 1 - The company announced on August 5 that it is transitioning from phase II to phase III clinical research for its new drug development [1] - Completion of phase II clinical research demonstrated good safety and preliminary efficacy of the drug [1] - The company has submitted relevant data and the phase III clinical plan to the CDE for review and communication [1]